These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21357659)

  • 1. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol.
    Casarosa P; Kollak I; Kiechle T; Ostermann A; Schnapp A; Kiesling R; Pieper M; Sieger P; Gantner F
    J Pharmacol Exp Ther; 2011 Jun; 337(3):600-9. PubMed ID: 21357659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
    Maleki-Yazdi MR; Beck E; Hamilton AL; Korducki L; Koker P; Fogarty C
    Respir Med; 2015 May; 109(5):596-605. PubMed ID: 25829298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models.
    Bouyssou T; Casarosa P; Naline E; Pestel S; Konetzki I; Devillier P; Schnapp A
    J Pharmacol Exp Ther; 2010 Jul; 334(1):53-62. PubMed ID: 20371707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action.
    Slack RJ; Barrett VJ; Morrison VS; Sturton RG; Emmons AJ; Ford AJ; Knowles RG
    J Pharmacol Exp Ther; 2013 Jan; 344(1):218-30. PubMed ID: 23131596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models.
    Aparici M; Gómez-Angelats M; Vilella D; Otal R; Carcasona C; Viñals M; Ramos I; Gavaldà A; De Alba J; Gras J; Cortijo J; Morcillo E; Puig C; Ryder H; Beleta J; Miralpeix M
    J Pharmacol Exp Ther; 2012 Aug; 342(2):497-509. PubMed ID: 22588259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease.
    Joos GF; Aumann JL; Coeck C; Korducki L; Hamilton AL; Kunz C; Aalbers R
    Respir Med; 2015 May; 109(5):606-15. PubMed ID: 25776199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol.
    Aparici M; Gavaldà A; Ramos I; Carcasona C; Otal R; Fernández-Blanco JA; Montero JL; García VM; López R; De Alba J; Doe C; Puig C; Vilella D; Miralpeix M
    Eur J Pharmacol; 2016 Jan; 770():61-9. PubMed ID: 26656755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of AZD9708, a novel, selective β2-adrenoceptor agonist with rapid onset and long duration of action.
    Nicholls DJ; Jordan S; Cadogan E; Lawson M; Austin RP; Paine SW; Gardiner P; Bonnert R; Connolly S; Young A
    Pulm Pharmacol Ther; 2012 Aug; 25(4):293-302. PubMed ID: 22659538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review.
    Melani AS
    Expert Opin Pharmacother; 2018 Oct; 19(14):1603-1611. PubMed ID: 30311516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.
    Wang J; Nie B; Xiong W; Xu Y
    J Clin Pharm Ther; 2012 Apr; 37(2):204-11. PubMed ID: 21740451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects.
    Malerba M; Radaeli A; Morjaria JB
    Drug Discov Today; 2012 May; 17(9-10):496-504. PubMed ID: 22119310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-acting beta-2-agonists in the treatment of asthma].
    Rochat T
    Schweiz Med Wochenschr; 1994 Oct; 124(39):1714-9. PubMed ID: 7939538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases.
    Sin DD; Man SF
    Eur J Pharmacol; 2006 Mar; 533(1-3):28-35. PubMed ID: 16457807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salmeterol Xinafoate.
    Anwar MM; El-Haggar RS; Zaghary WA
    Profiles Drug Subst Excip Relat Methodol; 2015; 40():321-69. PubMed ID: 26051688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
    Ohar JA; Donohue JF
    Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reassertion profiles of long acting β2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant β2-adrenoceptor.
    Patel S; Summerhill S; Stanley M; Perros-Huguet C; Trevethick MA
    Pulm Pharmacol Ther; 2011 Apr; 24(2):247-55. PubMed ID: 21134482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ▼Olodaterol--another LABA for COPD.
    Drug Ther Bull; 2015 Apr; 53(4):42-5. PubMed ID: 25858815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stable activation and desensitization of beta 2-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasi-irreversible binding to an exosite.
    Clark RB; Allal C; Friedman J; Johnson M; Barber R
    Mol Pharmacol; 1996 Jan; 49(1):182-9. PubMed ID: 8569705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and therapeutics of bronchodilators.
    Cazzola M; Page CP; Calzetta L; Matera MG
    Pharmacol Rev; 2012 Jul; 64(3):450-504. PubMed ID: 22611179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends.
    Montuschi P; Ciabattoni G
    J Med Chem; 2015 May; 58(10):4131-64. PubMed ID: 25587755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.